Patients prefer health media sites to user-generated content for medical info, says survey

Share this article:
Consumers continue to trust health magazines, websites and WebMD more than user-generated contribution sites like Wikipedia, Facebook or Twitter for medical information, according to a survey.

More than half of the adults surveyed – 54% – had consulted user-generated content for health info – compared to 68% who'd sought out info on news sites. However, almost half (48%) had searched WebMD.

Facebook sites are the fourth most-frequented source, according to the survey of 1,000 adults, conducted by Makovsky + Company, with 11% of Americans looking for medical info there. But Facebook sites created by peers were ranked the least trusted by 26% of respondents (Facebook sites for patient groups and communities fared much better).

Overall, patient communities' sites were visited by a scant 7% of respondents. Pharma company-sponsored pages ranked dead last for visits, with just 6% of respondents visiting disease awareness pages and branded treatment pages.

The results indicate a tiered approach to health info online that privileges trusted brands over user-generated content, said Makovsky execs.

“Peer to peer communication establishes an emotional, ‘tell me your story' connection,” said Makovsky health practice leader Gil Bashe. “Yet when it comes to healthcare information, patients still trust the experts.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...